GlassScriptPhysician profile
Frank Demery
NPI 1376592956
$12,016.55
in general payments reported to CMS, 2019-2025
53 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $1,721 · 2021: $1,896 · 2022: $1,536 · 2023: $1,888 · 2024: $1,881 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,913 · Education: $38.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,912.82 |
| Education | $38.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,634.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,454.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,249.16 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $985.50 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Gilead Sciences, INC. | $886.95 | 2019-2025 | |
| Lilly USA, LLC | $756.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $559.28 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.73 | 2019-2025 | Vpriv |
| Corium, LLC | $311.34 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $300.05 | 2019-2025 | Doc Band |
| Amarin Pharma, INC. | $286.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $282.55 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Supernus Pharmaceuticals, INC. | $236.47 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $233.87 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Exact Sciences Corporation | $192.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Demery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.